Clinical Trial Update: A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a PD-1 inhibitor with or without a vitamin D analog for maintenance therapy in pancreatic cancer has completed enrollment with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreas Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• PD1 inhibitor (PD-1 inhibitor)
• Vitamin D analog

Snippet

Sponsor: Translational Genomics Research Institute | Conditions: Pancreatic Cancer, Pancreas Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-12-27